A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease

首次发布于 2016 年 11 月 15 日

An Observational Study in Children With CLN2 Batten Disease

首次发布于 2020 年 7 月 8 日

A Retrospective, Natural History Study in Children With CLN2

首次发布于 2020 年 7 月 21 日

CLK2 inhibitor (Biosplice Therapeutics)

CLK2 inhibitors(China Pharmaceutical University)

CLK2 inhibitor (oral, solid tumors), Biosplice Therapeutics

Biosplice Submits First Potential Disease-Modifying Osteoarthritis Drug to FDA

Incyte's ALK2 Inhibitor Zilurgisertib Fumarate Shows Promise Across Multiple Hematologic Disorders

FDA Expands Brineura Approval to Include All Ages with CLN2 Disease